finanzen.net

MorphoSys Aktie WKN: 663200     / ISIN: DE0006632003    

114,10EUR
±0,00EUR
±0,00%
21.02.2020
KAUFEN
VERKAUFEN
mehr Daten anzeigen

MorphoSys Aktien News

31.01.20
MorphoSys AG : Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (Investegate)
13.01.20
MorphoSys AG : Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab (Investegate)
12.12.19
MorphoSys AG : Preliminary announcement of the publication of quarterly reports and quarterly/interim statements (Investegate)
12.12.19
MorphoSys AG : Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] (Investegate)
11.12.19
MorphoSys AG : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (Investegate)
03.12.19
MorphoSys AG : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (Investegate)
30.11.19
Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine (Reuters)
29.11.19
MorphoSys AG : Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (Investegate)
21.11.19
Chief scientist quits at Germany's Morphosys ahead of product launch (Reuters)
20.11.19
MorphoSys AG : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (Investegate)
18.11.19
MorphoSys AG : Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis (Investegate)
06.11.19
MorphoSys AG : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (Investegate)
30.10.19
MorphoSys AG (MOR) Q3 2019 Earnings Call Transcript (MotleyFool)
15.10.19
MorphoSys AG : Correction of a release from 11/10/2019 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (Investegate)
14.10.19
MorphoSys AG : MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China (Investegate)
04.09.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
22.08.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
22.08.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
19.08.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
07.08.19
MorphoSys AG (MOR) Q2 2019 Earnings Call Transcript (MotleyFool)
06.08.19
DGAP-News: MorphoSys AG Reports Second Quarter 2019 Financial Results (EQS Group)
06.08.19
DGAP-News: MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL (EQS Group)
06.08.19
DGAP-News: MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency (EQS Group)
02.08.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
02.08.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
31.07.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
29.07.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
25.07.19
DGAP-News: Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019 (EQS Group)
24.07.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
09.07.19
DGAP-DD: MorphoSys AG english (EQS Group)
08.07.19
DGAP-News: MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology (EQS Group)
03.07.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
03.07.19
DGAP-News: MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019 (EQS Group)
03.07.19
DGAP-Adhoc: Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK (EQS Group)
28.06.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
26.06.19
DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
24.06.19
DGAP-Adhoc: Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer (EQS Group)
24.06.19
DGAP-News: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer (EQS Group)
24.06.19
DGAP-Adhoc: Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer (EQS Group)
24.06.19
Stocks to watch: MorphoSys, Daimler, BT, Admiral, Bakkavor, RWE (Financial Times)
Seite: 123456789...12

MorphoSys News

MorphoSys News: auf dieser Seite finden Sie alle MorphoSys News und Nachrichten zur MorphoSys Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch MorphoSys News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um MorphoSys News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
TeslaA1CX3T
NEL ASAA0B733
Deutsche Bank AG514000
Ballard Power Inc.A0RENB
Microsoft Corp.870747
Wirecard AG747206
Daimler AG710000
PowerCell Sweden ABA14TK6
Apple Inc.865985
Allianz840400
Amazon906866
Deutsche Telekom AG555750
SteinhoffA14XB9
Plug Power Inc.A1JA81
BASFBASF11